GLMD Key Statistics, Chart & Performance
The current stock price of GLMD is 0.8499 USD. In the past month the price decreased by -26.73%. In the past year, price decreased by -70.69%.
GLMD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.72 | 396.12B | ||
| AMGN | AMGEN INC | 15.09 | 177.76B | ||
| GILD | GILEAD SCIENCES INC | 14.73 | 149.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.06 | 119.17B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.8 | 84.19B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 783.14 | 52.76B | ||
| INSM | INSMED INC | N/A | 36.31B | ||
| NTRA | NATERA INC | N/A | 33.06B | ||
| BIIB | BIOGEN INC | 11.11 | 27.29B | ||
| INCY | INCYTE CORP | 16.5 | 20.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.6 | 21.14B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.76B |
Related stock screener links
About GLMD
Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). The firm is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The firm's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The firm's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
Company Info
GALMED PHARMACEUTICALS LTD
16 Tiomkin Street
TEL AVIV-YAFO 6578317 IL
CEO: Allen Baharaff
Employees: 3
Phone: 97236938448
GALMED PHARMACEUTICALS LTD / GLMD FAQ
Can you describe the business of GALMED PHARMACEUTICALS LTD?
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). The firm is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The firm's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The firm's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
What is the stock price of GALMED PHARMACEUTICALS LTD today?
The current stock price of GLMD is 0.8499 USD. The price increased by 1.87% in the last trading session.
Does GALMED PHARMACEUTICALS LTD pay dividends?
GLMD does not pay a dividend.
What is the ChartMill rating of GALMED PHARMACEUTICALS LTD stock?
GLMD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for GALMED PHARMACEUTICALS LTD?
GALMED PHARMACEUTICALS LTD (GLMD) operates in the Health Care sector and the Biotechnology industry.
What is the Price/Earnings (PE) ratio of GALMED PHARMACEUTICALS LTD (GLMD)?
GALMED PHARMACEUTICALS LTD (GLMD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.6).
Can you provide the market cap for GALMED PHARMACEUTICALS LTD?
GALMED PHARMACEUTICALS LTD (GLMD) has a market capitalization of 6.07M USD. This makes GLMD a Nano Cap stock.
GLMD Technical Analysis
GLMD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GLMD. The financial health of GLMD is average, but there are quite some concerns on its profitability.
GLMD Financial Highlights
Over the last trailing twelve months GLMD reported a non-GAAP Earnings per Share(EPS) of -3.6. The EPS increased by 85.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.31% | ||
| ROE | -45.52% | ||
| Debt/Equity | 0 |